Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias

Marti, Matteo, Rodi, Donata, Li, Qin, Guerrini, Remo, Fasano, Stefania, Morella, Ilaria, Tozzi, Alessandro, Brambilla, Riccardo, Calabresi, Paolo, Simonato, Michele, Bezard, Erwan and Morari, Michele 2012. Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias. Journal of Neuroscience 32 (46) , pp. 16106-16119. 10.1523/JNEUROSCI.6408-11.2012

[img]
Preview
PDF - Published Version
Available under License Creative Commons Attribution Non-commercial Share Alike.

Download (2MB) | Preview

Abstract

In the present study we investigated whether the neuropeptide nociceptin/orphanin FQ (N/OFQ), previously implicated in the pathogenesis of Parkinson's disease, also affects L-DOPA-induced dyskinesia. In striatal slices of naive rodents, N/OFQ (0.1–1 μM) prevented the increase of ERK phosphorylation and the loss of depotentiation of synaptic plasticity induced by the D1 receptor agonist SKF38393 in spiny neurons. In vivo, exogenous N/OFQ (0.03–1 nmol, i.c.v.) or a synthetic N/OFQ receptor agonist given systemically (0.01–1 mg/Kg) attenuated dyskinesias expression in 6-hydroxydopamine hemilesioned rats primed with L-DOPA, without causing primary hypolocomotive effects. Conversely, N/OFQ receptor antagonists worsened dyskinesia expression. In vivo microdialysis revealed that N/OFQ prevented dyskinesias simultaneously with its neurochemical correlates such as the surge of nigral GABA and glutamate, and the reduction of thalamic GABA. Regional microinjections revealed that N/OFQ attenuated dyskinesias more potently and effectively when microinjected in striatum than substantia nigra (SN) reticulata, whereas N/OFQ receptor antagonists were ineffective in striatum but worsened dyskinesias when given in SN. Quantitative autoradiography showed an increase in N/OFQ receptor binding in striatum and a reduction in SN of both unprimed and dyskinetic 6-hydroxydopamine rats, consistent with opposite adaptive changes of N/OFQ transmission. Finally, the N/OFQ receptor synthetic agonist also reduced dyskinesia expression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated dyskinetic macaques without affecting the global parkinsonian score. We conclude that N/OFQ receptor agonists may represent a novel strategy to counteract L-DOPA-induced dyskinesias. Their action is possibly mediated by upregulated striatal N/OFQ receptors opposing the D1 receptor-mediated overactivation of the striatonigral direct pathway.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Biosciences
Subjects: R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
Additional Information: Pdf uploaded in accordance with publisher's policy at http://www.jneurosci.org/site/misc/ifa_policies.xhtml#copyright (accessed 26/02/2014).
Publisher: Society for Neuroscience
ISSN: 0270-6474
Date of First Compliant Deposit: 30 March 2016
Last Modified: 11 Apr 2019 22:10
URI: http://orca.cf.ac.uk/id/eprint/41677

Citation Data

Cited 26 times in Google Scholar. View in Google Scholar

Cited 25 times in Scopus. View in Scopus. Powered By Scopus® Data

Cited 14 times in Web of Science. View in Web of Science.

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics